CoChat

Mipomersen is a Promising Therapy in the Management of Hypercholesterolemia: A Meta-Analysis of Randomized Controlled Trials

Li, Na, Li, Qing, Tian, Xia-Qiu, Qian, Hai-Yan, Yang, Yue-Jin · 2014 · American Journal of Cardiovascular Drugs

The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.

Abstract

Introduction By inhibiting apolipoprotein B (ApoB) synthesis, mipomersen can significantly reduce ApoB-containing lipoproteins in hypercholesterolemic patients.Objective This study sought to ascertain both the extent to which mipomersen can decrease ApoB-containing lipoproteins and the safety of mipomersen therapy.Methods Studies were identified through PubMed, CENTRAL, Embase, Clinical Trials, reviews, and reference lists of relevant papers. The efficacy endpoints were the changes in low-density lipoprotein cholesterol (LDL-C), non-high-density lipoprotein cholesterol (non-HDL-C), ApoB, and lipoprotein (a) [Lp(a)]. The safety endpoints were the incidence of injection-site reactions, flu-like symptoms, and elevated transaminases.Results Six randomized controlled trials with 444 patients were included in the analysis. Compared with the placebo group, patients who received mipomersen therapy had a significant reduction in LDL-C (33.13%), as well as a reduction in non-HDL-C (31.70%), ApoB (33.27%), and LP(a) (26.34%). Mipomersen therapy was also associated with an obvious increase in injection-site reactions with an odds ratio (OR) of 14.15, flu-like symptoms with an OR of 2.07, and alanine aminotransferase levels ≥ 3 × the upper limit of normal with an OR of 11.21.Conclusions Mipomersen therapy is effective for lowering ApoB-containing lipoproteins in patients with severe hypercholesterolemia. Future studies exploring how to minimize side effects of mipomersen therapy are needed.

Overview

Integrity signals

Registry

Crossref · 10.1007/s40256-014-0077-0

Cites

40 of 40 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Research works printed but not linked: 1

  1. Genzyme and Isis provide update on CHMP opinion on KYNAMRO™ (mipomersen). Press release, Genyzme and Isis Pharmaceuticals. http://en.sanofi.com/Images/31557_20121214_KYNAMRO_en.pdf . Accessed 15 Nov 2013.

Cited by

See all 50

Metadata

Authors
Li, N., Li, Q., Tian, X.-Q., Qian, H.-Y., & Yang, Y.-J.
Affiliations
Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
Venue
American Journal of Cardiovascular Drugs
Published
2014-06-11
Volume
14
Issue
5
Pages
367-376
ISSN
  • 1175-3277 (ISSN-L)
  • 1179-187X
OpenAlex
W2133781918
Cited by
45
References
40
Citations by year
2024: 6 · 2023: 1 · 2022: 3 · 2021: 5 · 2020: 3 · 2019: 3 · 2018: 3 · 2017: 5 · 2016: 7 · 2015: 7 · 2014: 2
FWCI
1.32
Type
journal article
Language
en
Open access
closed
Licence
www.springer.com/tdm (tdm)
Locations
  • American Journal of Cardiovascular Drugs (publishedVersion)
  • PubMed (publishedVersion)
Funders
National Natural Science Foundation of China
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
Keywords
mipomersen, hypercholesterolemia, apolipoprotein B, LDL cholesterol, non-HDL cholesterol, lipoprotein(a), apolipoprotein B-containing lipoproteins, drug safety, injection site reactions, flu-like symptoms, elevated liver enzymes, PCSK9 inhibition
MeSH terms
Adult, Anticholesteremic Agents, Female, Humans, Hypercholesterolemia, Cholesterol, HDL, Cholesterol, LDL, Male, Middle Aged, Oligonucleotides, Randomized Controlled Trials as Topic, Treatment Outcome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.